Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Key Points: Blocking STAT3 in acute myeloid leukemia cells stimulates their TLR9-induced immunogenicity and antigen-specific activation of CD8+ T cells. Systemic delivery of CpG-Stat3 siRNA generates potent adaptive immune responses eradicating disseminated acute myeloid leukemia in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 3×
“Earlier studies indicated that STAT3 activation is also common in many tumor-associated myeloid cell populations that contribute to tumorigenesis.(12) It is an attractive but challenging target for cancer therapy, because pharmacologic inhibition of nonenzymatic proteins has proved to be difficult.”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 plays a role in promoting AML cell proliferation and survival, but whether it contributes to immune evasion has not been clearly demonstrated.(7,10,11) Earlier studies indicated that STAT3 activation is also common in many tumor-associated myeloid cell populations that contribute to tumorigenesis.”
BackgroundThe wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · cited 1×
“our study, the increased STAT3 activity in AML cells correlated with elevated plasma levels of IL-6, which is known as a hallmark of cancer-induced inflammations and a major STAT3 activator.(47) High plasma levels of IL-6 are an unfavorable prognostic factor for survival in AML patients.”
BackgroundQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“An increased ratio of tumor-infiltrating effector CD8 T cells to Tregs is an indicator of successful cancer immunotherapy correlated to tumor rejection.(32,49) This is likely an indirect effect of CpG-Stat3 siRNA–mediated induction of tumor antigen–specific responses, as confirmed in two independent AML models in vivo…”
BackgroundZhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395
Self-citationA Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
Self-citation
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
Metadata
- Authors
- Hossain, D. M. S., Dos Santos, C., Zhang, Q., Kozlowska, A., Liu, H., Gao, C., Moreira, D., Swiderski, P., Jozwiak, A., Kline, J., Forman, S., Bhatia, R., Kuo, Y.-H., & Kortylewski, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-01-02
- Volume
- 123
- Issue
- 1
- Pages
- 15-25
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1993491016
- Cited by
- 103
- References
- 8
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. https://app.cochat.ai/papers/10.1182/blood-2013-07-517987
- The paper
- Hossain, D. M. S., Dos Santos, C., Zhang, Q., Kozlowska, A., Liu, H., Gao, C., Moreira, D., Swiderski, P., Jozwiak, A., Kline, J., Forman, S., Bhatia, R., Kuo, Y.-H., & Kortylewski, M. (2014). Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. https://doi.org/10.1182/blood-2013-07-517987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.